Opus Genetics (NASDAQ: IRD) recently received a number of ratings updates from brokerages and research firms: 9/10/2026 – Opus Genetics had its price target raised by Wedbush from $10.00 to $13.00. They now have an “outperform” rating on the stock. 9/9/2026 – Opus Genetics had its price target raised by Chardan Capital from $13.00 to […]